Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment ...

Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...